Solvay Reports Higher Sales and Profit; Focuses on 'Optimal Reinvestment' Following Disposal of Pharma Unit
07:18 AM | July 29, 2010 | Natasha Alperowicz
Solvay's recurring group operating result (Rebit) from continuing operations, following the sale of its pharmaceuticals business, rose to €183 million ($237.8 million) in the second quarter of this...
This information is only available to subscribers.
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.